Abeers Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 29-07-2024
- Paid Up Capital ₹ 0.10 M
as on 29-07-2024
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 30.00 M
as on 29-07-2024
- Revenue %
(FY 2023)
- Profit -106.88%
(FY 2023)
- Ebitda 93.68%
(FY 2023)
- Net Worth -212.00%
(FY 2023)
- Total Assets -0.80%
(FY 2023)
About Abeers Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹3.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Charminder Kaur, Mini Gupta, and Amarjeet Singh serve as directors at the Company.
- CIN/LLPIN
U24232DL2012PTC236003
- Company No.
236003
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Abeers Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Charminder Kaur  | Director | 17-May-2012 | Current |
| Mini Gupta | Additional Director | 03-Apr-2024 | Current |
| Amarjeet Singh | Director | 17-May-2012 | Current |
Financial Performance and Corporate Structure Insights of Abeers Pharmaceuticals.
Abeers Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 106.88% decrease in profit. The company's net worth observed a substantial decline by a decrease of 212%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abeers Pharmaceuticals?
In 2023, Abeers Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abeers Marketing Private Limited
Active 18 years 6 monthsCharminder Kaur and Mini Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 25 Sep 2012 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Abeers Pharmaceuticals?
Unlock and access historical data on people associated with Abeers Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abeers Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abeers Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
